Cargando…
Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers
Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to...
Autores principales: | Jung, Sang-hoon, Chae, Jung-woo, Song, Byung-jeong, Kwona, Kwang-il |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157012/ https://www.ncbi.nlm.nih.gov/pubmed/25237332 |
Ejemplares similares
-
Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects
por: Ju, Gehang, et al.
Publicado: (2020) -
Formulation and characterization of orodispersible tablet of glimepiride
por: Kinani, Ahmad AB Yosef, et al.
Publicado: (2022) -
Bioequivalence Study of 100-mg Cilostazol Tablets in Healthy Thai Adult Volunteers
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2019) -
Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast
por: Knorr, Barbara, et al.
Publicado: (2010) -
Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2023)